BioLight Life Sciences Company Description

BioLight Life Sciences Ltd. engages in the investment, development, management, and commercialization of products in the fields of advanced medical devices, pharmaceuticals, diagnostics, and digital medicine in Israel.

The company offers TeaRx, a diagnostic platform intended for point-of-care testing of ophthalmic pathologies through multi-parameter composition analysis of the tear fluid; TeaRx Dry Eye Syndrome; and Ocuvia, a front-to-back ocular treatment that includes ocudrip and ocugrid.

It also provides Eye-D technology which treats glaucoma by the insertion of a sub-conjunctival implant; and Ocular D, a product for treating dryness in the eye with integrated vitamin D.

In addition, the company engages in the development of drugs for treating eye diseases using a technological platform that enhances the transmission of active substances based on nanostructures.

The company was formerly known as Bio Light Israeli Life Sciences Investments Ltd. and changed its name to BioLight Life Sciences Ltd. in February 2016.

BioLight Life Sciences Ltd. was incorporated in 2005 and is based in Ramat Gan, Israel.

BioLight Life Sciences Ltd.

Country	Israel
Founded	2005
Industry	Biotechnology
Sector	Healthcare
Employees	4
CEO	Yaacov Michlin

Contact Details

Address: Aba Hillel Silver 12 Ramat Gan, 5250606 Israel
Phone	972 7 327 53400
Website	bio-light.co.il

Stock Details

Ticker Symbol	BOLT
Exchange	Tel Aviv Stock Exchange
Fiscal Year	January - December
Reporting Currency	ILS
ISIN Number	IL0010952237
SIC Code	3845

Key Executives

Name	Position
Shimon Gross	Chief Executive Officer of Diagnostir
Yaacov Michlin	Chief Executive Officer
Yifftach Biel CPA	Chief Financial Officer
Karin Gurevitz	Vice President, Legal Advisor, Chief Compliance Officer and Company Secretary
Dr. Ron Neumann M.D.	Chief Medical Officer and Member of Scientific Advisory Board